Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Enteric coating is designed to delay absorption until the drug reaches the small intestine, potentially reducing gastric irritation.
## Primary Indications
* **Cardiovascular prophylaxis:** Prevention of myocardial infarction and stroke in patients with established cardiovascular disease or risk factors.
* **Analgesia and antipyresis:** For mild to moderate pain and fever (less common use for enteric-coated formulations due to delayed onset).
* **Anti-inflammatory:** Management of inflammatory conditions (less common use for enteric-coated formulations).
## Adult Dosing
* **Cardiovascular prophylaxis:**
* **Secondary prevention:** 75 mg to 325 mg once daily.
* **Primary prevention:** 75 mg to 100 mg once daily. Some guidelines suggest 100 mg daily or 75-100 mg every other day.
* **Higher doses (e.g., 325 mg) may be used initially for acute events like myocardial infarction, followed by a lower maintenance dose.**
* **Analgesia/Antipyresis:** 325 mg to 650 mg every 4 to 6 hours as needed. Maximum daily dose: 4000 mg.
* **Anti-inflammatory:** 3000 mg to 6000 mg daily, divided into multiple doses.
## Pediatric Dosing
* Aspirin is generally **contraindicated in children and adolescents under 19 years of age** with viral infections (e.g., influenza, varicella) due to the risk of Reye's syndrome.
* Specific pediatric dosing for indications other than those with contraindications is typically based on weight and indication and requires careful consideration and physician guidance.
## Dose Adjustments
* No dose adjustment is typically required for renal or hepatic impairment, but caution is advised. Significant hepatic or renal dysfunction may warrant dose reduction or discontinuation.
## Contraindications
* Hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* History of bronchospasm, asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
* Active peptic ulcer disease or gastrointestinal bleeding.
* Children and adolescents under 19 years of age with viral infections (risk of Reye's syndrome).
* Severe hepatic or renal impairment.
* Severe heart failure.
* Coagulation disorders.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, GI bleeding, ulceration.
* **Hematologic:** Increased bleeding time, bruising, epistaxis, menorrhagia.
* **Otic:** Tinnitus, hearing loss (often dose-related).
* **Respiratory:** Bronchospasm (especially in aspirin-sensitive individuals).
* **Dermatologic:** Rash, urticaria.
* **Renal:** Renal insufficiency, papillary necrosis (with chronic use).
* **Hepatic:** Hepatotoxicity (rare).
* **Metabolic:** Metabolic acidosis.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, direct oral anticoagulants):** Increased risk of bleeding.
* **Other NSAIDs (including COX-2 inhibitors):** Increased risk of GI toxicity, bleeding, and reduced cardioprotective effect of low-dose aspirin.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Alcohol:** Increased risk of GI irritation and bleeding.
* **Methotrexate:** Increased methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Reduced efficacy of uricosuric agent.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** May reduce antihypertensive effect and increase risk of renal dysfunction.
* **Selective Serotonin Reuptake Inhibitors (SSRIs):** Increased risk of bleeding.
## Monitoring
* **Gastrointestinal symptoms:** Monitor for signs and symptoms of GI bleeding (e.g., melena, hematemesis, abdominal pain).
* **Bleeding:** Monitor for signs of excessive bleeding or bruising.
* **Renal function:** Periodically monitor in patients with risk factors for renal impairment.
* **Hepatic function:** Periodically monitor in patients with risk factors for hepatic impairment.
* **Tinnitus/hearing loss:** May indicate over-dosage.
## Clinical Pearls
* Enteric-coated aspirin should not be crushed or chewed.
* For acute cardiovascular events, immediate-release aspirin is preferred for faster absorption and onset of action.
* Concomitant use with other NSAIDs should be avoided if possible. If NSAID use is necessary, consider separating administration times or using a COX-2 selective inhibitor cautiously.
* The cardioprotective benefits of low-dose aspirin are generally considered to outweigh the risks in appropriate patient populations, but individual risk-benefit assessment is crucial.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and recommendations may vary based on individual patient factors and local protocols.*
